RAC Regulatory Agency Interactions Questions and Answers

Question 1

A sponsor's novel drug development program is on clinical hold due to safety concerns.
The sponsor has submitted a complete response to the hold issues, but the agency and sponsor agree that the path forward is unclear.
Which type of formal meeting with the FDA is most appropriate to request to resolve the impasse?

Accepted Answer

Type A Meeting

Answer

Type B Meeting

Answer

Type C Meeting

Answer

Pre-IND Meeting

Question 2

When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

Accepted Answer

Specific, forward-looking questions for the agency on which feedback is sought.

Answer

A complete list of all anticipated marketing claims.

Answer

Detailed financial projections for the first five years.

Answer

The final, locked-down version of the device's Instructions for Use (IFU).

Question 3

A pharmaceutical manufacturer receives an FDA Form 483 with three inspectional observations at the close-out of a GMP inspection. What is the most critical immediate action for the company?

Accepted Answer

Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs).

Answer

Wait for the official Establishment Inspection Report (EIR) before taking any action.

Answer

Immediately file a formal dispute with the agency's legal counsel.

Answer

Begin remediation but refrain from communicating with the FDA until all actions are complete.

Question 4

A company is developing a novel medicinal product in Europe and seeks guidance from the European Medicines Agency (EMA) on its proposed clinical development strategy. Which formal procedure should the company utilize for this purpose?

Accepted Answer

Scientific Advice

Answer

Centralised Procedure Application

Answer

Marketing Authorisation Application

Answer

Mutual Recognition Procedure

Question 5

Following a formal meeting with the FDA, the sponsor receives the agency's official meeting minutes and identifies a significant discrepancy regarding a key agreement on the statistical analysis plan. What is the most appropriate action for the sponsor?

Accepted Answer

Formally contact the FDA within the specified timeframe to request a clarification or correction to the minutes.

Answer

Accept the FDA's minutes as legally binding and immediately alter the clinical trial design.

Answer

Proceed with the trial based on their own understanding and address the discrepancy in the final NDA submission.

Answer

Send a letter of complaint directly to the FDA Ombudsman.

Question 6

Which of the following best describes the role of an FDA Advisory Committee in the product approval process?

Accepted Answer

To provide independent, expert advice and recommendations to the FDA, which the agency considers in its final decision.

Answer

To negotiate labeling and post-marketing commitments directly with the sponsor.

Answer

To provide a final, legally binding decision on the approvability of a product.

Answer

To conduct its own independent audits of the sponsor's clinical trial data.